This bill proposes several updates to current statutes regarding the expenditure of public funds for health insurance and genetic sequencing procedures. Under the new provisions, public monies may not be spent on genetic sequencing procedures performed using devices produced by companies that are either domiciled in or substantially controlled by companies from designated foreign adversaries, which include nations such as China, Russia, Iran, and North Korea. The bill also introduces definitions for terms such as "company," "domiciled," "foreign adversary," and "genetic sequencing," clarifying the scope of the prohibitions and the entities affected.

Additionally, the bill modifies existing language regarding the spending of public funds for health insurance coverage for state employees and their dependents. It replaces the term "expend" with "spend" in multiple sections and makes technical adjustments to ensure consistency in terminology. The bill also specifies that public funds cannot be used to cover premiums for health insurance continued by surviving spouses of employees. Overall, these changes aim to enhance the regulation of public spending in relation to health insurance and genetic sequencing, particularly concerning national security concerns.

Statutes affected:
Introduced Version: 38-651, 38-651.01, 38-1114, 38-1141, 38-652, 15-388, 15-187.01, 38-656
House Engrossed Version: 38-651, 38-651.01, 38-1114, 38-1141, 38-652, 15-388, 15-187.01, 38-656